Capitulo1
Capitulo2
Capitulo3
Capitulo4
Capitulo5
Capitulo6
Capitulo7
Capitulo8
Capitulo2
Capitulo3
Capitulo11
Capitulo12
Capitulo13
Capitulo14
Capitulo15
Capitulo16
Capitulo17

1. Harris MI: Summary. In Diabetes in America. NIH Publication No. 95-1468. Edited by Harris MI, Cowie CC, Stern MP, et al. Washington, DC: US Government Printing Office; 1995:1–14.

2. De Fronzo RA: Lilly Lecture 1987:The triumvirate: b cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988, 37:667–687.

3. Pratley RE,Weyer C:The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabetologia 2001, 44(8):929–945.

4. Reaven GM: Role of insulin resistance in human disease. Diabetes 1988, 37:1596–1607.

5. Fagan TC, Deedwania PC:The cardiovascular dysmetabolic syndrome. Am J Med 1998, 105(1A):77S–82S.

6. King GL, Brownlee M:The cellular and molecular mechanisms of diabetic complications. Endocrinol Metab Clin North Am 1996, 25:255–270.

7. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813–820.

8. United Kingdom Prospective Diabetes Study Group: Intensive blood-glucose control with sulfonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352(9131):837–853.

9. United Kingdom Prospective Diabetes Study Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352(9131):854–865.

10. United Kingdom Prospective Diabetes Study Group:Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998, 7160:703–713.

11. Reaven GM: Multiple CHD risk factors in type 2 diabetes: beyond hyperglycemia. Diabetes, Obesity and Metabolism 2002, 4(Suppl 1):S13–S18.

12. Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346(6):393–403.

13. Garber AJ:Vascular disease and lipids in diabetes. Med Clin North Am1998, 82:931–948.

14. Aiello LP, Cavallerano J, Bursell S: Diabetic eye disease. Endocrinol Metab Clin North Am 1996, 25:271–291.

15. American Diabetes Association: Position statement: Diabetic retinopathy. Diabetes Care 2002, 25:S90–S93.

16. American Diabetes Association: Direct and Indirect Costs of Diabetes inthe United States in 1992. Alexandria,VA:American DiabetesAssociation, 1993.

17. American Diabetes Association: Position statement: Diabetic nephropathy. Diabetes Care 2002, 25:S85–S89.

18. Marks JB, Raskin P: Nephropathy and hypertension in diabetes. Med Clin North Am 1998, 82:877–907.

19. Friedman E: Renal syndromes in diabetes. Endocrinol Metab Clin North Am 1996, 25:293–324.

20. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355(9200):253–259.

21. Harati Y: Diabetes and the nervous system. Endocrinol Metab Clin North Am 1996, 25:325–359.

22. Boulton AJM, Malik RA: Diabetic neuropathy. Med Clin North Am 1998, 82:909–929.

23. Levin ME: Foot lesions in patients with diabetes mellitus. Endocrinol Metab Clin North Am 1996, 25:447–462.

24. American Diabetes Association: Position statement: foot care in diabetes. Diabetes Care 2002, 25(Suppl):S69–S70.

25. Hakim LS, Goldstein I: Diabetic sexual function. Endocrinol Metab Clin North Am 1996, 25:379–400.

26. Zimmet PZ,Alberti KGMM:The changing face of macrovascular disease in NIDDM:An epidemic in progress. Lancet 1997, 350(SI):1–4.

27. Krowelski AS,Warram JH,Valsania P, et al.: Evolving natural history of coronary artery disease in diabetes mellitus. Am J Med 1991, 90(Suppl 2A):56S–61S.

28. Kuusisito J, Mykannen L, Pyorala K, et al.: NIDDM and its metabolic control predict coronary artery disease in elderly subjects. Diabetes 1994, 43:960–967.

29. American Diabetes Association: Position statement: management of dyslipidemia in adults with diabetes mellitus. Diabetes Care 2002, 25:S74–S77.

30. Eastman RC, Javitt JC, Herman WH, et al.: Model of complications in NIDDM:Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997, 20:735–744.

 voltar